Medical technology company Becton, Dickinson and Company (BD) has introduced a new family of reagents in a bid to reduce the limits of flow cytometry and expedite the development of drugs for diseases.

The BD Horizon RealYellow 586 Reagents are developed leveraging a novel BD dye technology and artificial intelligence (AI) guidance to provide researchers with deeper insights when compared to traditional fluorochromes.

According to a BD statement, the launch also marks the first fluorochrome in a series from the BD Horizon RealYellow and RealBlue Reagents product family.

Flow cytometry is a technology that enables researchers to identify and assess the characteristics of single cells.

The technique allows the in-depth study of cells to gain improved understanding of the immune system as well as facilitate the discovery of new biomarkers and treatments.

Fluorochromes, or fluorescent dyes, are a key component in such studies. These photoreactive chemical compounds are excited by laser light and help in the identification of key traits in a cell.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The newly introduced BD Horizon RealYellow 586 Reagents are also optimised for spectral flow cytometry, which allows the measurement of additional characteristics from a single sample.

The company expects that the reagents will help researchers conduct high-dimensional research.

BD biosciences research and clinical solutions vice-president and general manager Steve Conly said: “By overcoming this longstanding limitation in flow cytometry, scientists will now be able to more accurately and confidently study cells of interest, which can streamline discovery research and help unlock potential therapies for disease in a broad range of fields, including virology and oncology.

“With BD Horizon RealYellow and RealBlue Reagents, BD demonstrates its continued leadership in the exciting field of spectral flow cytometry. The new reagents will complement future products that leverage BD CellView Image Technology, our new technology that adds fluorescence imaging and image-based decisioning to sort individual cells at high speed based on the visual details of each cell, to empower researchers with a truly unique solution for cutting-edge flow cytometry.”

Currently, BD Horizon RealYellow 586 Reagents are available globally through online channels and local sales representatives.

Earlier in the year, BD entered a partnership to incorporate the BD Veritor At-Home Covid-19 Test directly into ReturnSafe’s testing management platform.